Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018, at 4:30 pm (PT).
The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at http://investor.fiveprime.com/events.cfm or directly at https://jpmorgan.metameetings.net/events/healthcare18/sessions/13430-five-prime-therapeutics/webcast. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and the focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.
CONTACT:
Heather Rowe
Senior Director, Investor Relations and Corporate Communications
415-365-5737
[email protected]
